1	U-shaped effect of blood pressure on structural OCT metrics and retinal blood flow
2	autoregulation in ophthalmologically healthy subjects
3	
4	Konstantinos Pappelis, <sup>1,2</sup> Nomdo M. Jansonius <sup>1,2</sup>
5	
6	1. Department of Ophthalmology, University of Groningen, University Medical Center
7	Groningen, Groningen, The Netherlands
8	2. Graduate School of Medical Sciences (Research School of Behavioural and Cognitive
9	Neurosciences), University of Groningen, Groningen, The Netherlands
10	
11	Correspondence: K. Pappelis, Dept. of Ophthalmology, University Medical Center Groningen,
12	P.O.Box 30.001, 9700 RB Groningen, Netherlands. Phone: +31 50 3612510; Fax: +31 50
13	3611709; e-mail: k.pappelis@rug.nl
14	
15	<u>E-mail co-authors:</u> n.m.jansonius@umcg.nl
16	
17	Running head: Blood pressure and structural OCT: a U-shaped association
18	
19	Conflict of interest: No conflicting relationships exist for any author.
20	
21	Financial support: European Union's Horizon 2020 Innovative Training Networks Program,
22	under the Marie Sklodowska – Curie grant, Project ID 675033. The funding organization had no
23	role in the design, conduct, analysis, or publication of this research.
24	
25	Word count: 4165 (main text); 350 (Abstract)
26	
27	Meeting presentation: European Association for Vision and Eye Research (EVER); Nice, 3rd-6th
28	October 2018.
29	
30	Keywords: glaucoma, optical coherence tomography, blood pressure, blood flow, autoregulation
31	
32	Abbreviations/Acronyms: AHT, arterial hypertension; AR, autoregulatory reserve; BMI, body
33	mass index; BP, blood pressure; CRAE, central retinal artery equivalent; CRVE, central retinal
34	vein equivalent; DBP, diastolic blood pressure; FD, fractal dimension; GCIPL, ganglion cell-

35	inner plexiform layer; IOP, intraocular pressure; IQR, interquartile range; LARL, lower
36	autoregulation limit; MAP, mean arterial pressure; mRNFL, macular retinal nerve fiber layer;
37	NTG, normal-tension glaucoma; OCT, optical coherence tomography; OCT-A, optical
38	coherence tomography-angiography; ONH, optic nerve head; OPP, ocular perfusion pressure;
39	pRNFL, peripapillary retinal nerve fiber layer; RBF, retinal blood flow; RGC, retinal ganglion cell;
40	RNFL, retinal nerve fiber layer; RPP, retinal perfusion pressure; RVR, retinal vascular
41	resistance; SBP, systolic blood pressure; SD, standard deviation; SEQ, spherical equivalent.
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59 00	
60 64	
61	
62 62	
03 64	
0 <del>4</del> 65	
66 66	
67	
68	

### 69 Abstract

70

71	Objective: 1) To investigate the effect of low blood pressure (BP), treated arterial hypertension
72	(AHT), and untreated AHT on the ganglion cell-inner plexiform layer (GCIPL) and the retinal
73	nerve fiber layer (RNFL) thickness of non-glaucomatous eyes and 2) to elucidate whether this
74	effect is related to crossing the lower limit of retinal blood flow (RBF) autoregulation.
75	
76	Design: Cross-sectional, case-control.
77	
78	Subjects: We included 96 eyes of 96 ophthalmologically healthy subjects (age 50-65).
79	Participants were prospectively recruited from a large-scale cohort study in the northern
80	Netherlands (n=167,000; Lifelines Biobank). They were allocated to four groups (low BP, normal
81	BP [controls], treated AHT, untreated AHT), based on information from previous visits and strict
82	distribution criteria.
83	
84	Methods: Inner retinal layer thicknesses were obtained with optical coherence tomography
85	(OCT). Fractal dimension of the superficial microvasculature was quantified with OCT-
86	angiography and customized software. Central retinal vessel diameters were obtained from
87	fundus images. BP and intraocular pressure measurements were also acquired. Measurements
88	were combined with a validated physiological model to estimate vascular outcome measures.
89	Structural and vascular metrics were compared across groups and mediation analysis was
90	performed.
91	
92	Main outcome measures: Structural: macular GCIPL and RNFL (mRNFL), peripapillary RNFL
93	(pRNFL) thickness. Vascular: RBF, retinal vascular resistance (RVR), autoregulatory reserve
94	(AR).

96	Results: Compared to controls, GCIPL was thinner in the low BP group (P=0.013), treated
97	hypertensives (P=0.007), and untreated hypertensives (P=0.007). Treated hypertensives
98	exhibited the thinnest mRNFL (P=0.001), temporal pRNFL (P=0.045), and inferior pRNFL
99	(P=0.034). In multivariable analysis, RBF was mediating the association of GCIPL thickness
100	with BP within the combined low BP group and controls (P=0.003), RVR together with AR were
101	mediating the same association within the combined treated hypertensives and controls
102	(P=0.001 and P=0.032), and RVR was mediating the association within the combined untreated
103	antihypertensives and controls ( <i>P</i> =0.022).
104	
105	Conclusions: We uncovered GCIPL and RNFL thinning related to both tails of the BP
106	distribution. GCIPL thinning was associated with reduced RBF autoregulatory capacity. This
107	predisposition to glaucomatous damage could explain the frequent epidemiological finding of
108	increased glaucoma risk in certain subgroups, such as subjects with nocturnal BP dipping or
109	aggressively treated AHT. Longitudinal studies could confirm this postulation.
110	
111	
112	
113	
114	
115	
116	
117	
118	
119	
120	

#### 121 Introduction

122

Glaucoma is a chronic optic neuropathy characterized by thinning of the retinal nerve
 fiber layer (RNFL), loss of retinal ganglion cells (RGCs), and progressive visual function
 decline.<sup>1</sup> While elevated intraocular pressure (IOP) is considered as the most important
 modifiable risk factor, glaucoma may also manifest in those with apparently normal IOP (normal tension glaucoma [NTG]).<sup>2-4</sup> Therefore, certain components of the disease remain elusive or
 insufficiently addressed.

129 It has been proposed that low or unstable blood supply could lead to reduced oxygenation of the RGCs.<sup>4,5</sup> Current assessment of RGC structure is based on Optical 130 131 Coherence Tomography (OCT), while its extensions, OCT-angiography (OCT-A) and Doppler 132 OCT, enable the non-invasive evaluation of retinal perfusion.<sup>6–8</sup> These methods have already revealed that reduced blood flow predicts visual field (VF) deterioration, independently of neural 133 134 tissue damage.<sup>9-11</sup> However, after the onset of the disease, it is impossible to disentangle if 135 perfusion deficits are the cause (low supply) or consequence (low demand) of glaucomatous 136 optic neuropathy (GON). This realization is known as the 'chicken-egg' dilemma in glaucoma. 137 From a hemodynamic perspective, blood flow is determined by the balance between ocular perfusion pressure (OPP) and vascular resistance.<sup>12</sup> Therefore, low blood pressure (BP) 138 139 could result in low OPP, thus increasing the risk for glaucoma incidence and progression, 140 possibly due to flow-mediated damage to the RGCs. Indeed, this has been observed in some 141 cross-sectional and longitudinal population-based studies.<sup>13–16</sup> However, other studies do not 142 confirm this finding, while there is also evidence that this association becomes relevant only when low BP manifests as pronounced nocturnal dipping.<sup>17,18</sup> On the other hand, while arterial 143 144 hypertension (AHT) is also frequently reported as a risk factor for glaucoma, conflicting results 145 exist on whether BP reduction exacerbates or protects from GON, possibly depending on 146 individual medication effects and on how aggressive the treatment strategy is.<sup>19–26</sup>

147 This study focuses on ophthalmologically healthy subjects, rather than glaucoma 148 subjects. This is essential, because the next logical step in approaching the 'chicken-egg' 149 dilemma is to move back in the disease time course and study the effect of BP on retinal blood 150 flow (RBF) and the RGCs, prior to any glaucoma onset. To investigate RBF, we look into the 151 retinal microcirculation, which demonstrates the ability of autoregulation, i.e., active modification 152 of vascular caliber in response to local signals.<sup>27</sup> This property protects the tissue from 153 ischemia, in case of OPP drops. Recently, we proposed and validated a microcirculation model 154 predicting which healthy subjects are more prone to hypoperfusion, by estimating their lower 155 autoregulation limit (LARL) through OCT-A, fundus imaging, and other clinical examinations.<sup>28</sup> 156 In the present study, we hypothesized an inverse U-shaped association between BP 157 status and structural OCT measures in non-glaucomatous eyes. While the detrimental effect of 158 AHT to the RGCs and their axons has been previously documented, this effect has not been 159 studied in subjects with low BP, nor has it been examined in combination with RBF 160 autoregulation.<sup>29-32</sup> Studies until now have used linear models to describe the association 161 between BP and structural OCT measures, thus potentially neglecting any signal coming from 162 the left tail of the distribution.<sup>33,34</sup>

163 Therefore, the aims of this study were 1) to investigate the effect of low BP, treated AHT, 164 and untreated AHT on the inner retinal layer thicknesses of non-glaucomatous eyes and 2) to 165 elucidate whether this effect is related to crossing the lower limit of RBF autoregulation. For this 166 purpose, we performed multimodal structural and vascular imaging in ophthalmically healthy 167 normotensive controls, treated arterial hypertensives, and individuals belonging to the lower and 168 higher (untreated) tails of the BP distribution. Participants were selected from the large-scale 169 population-based Lifelines cohort, which enabled us to study the real extremes, especially from 170 the low BP tail, in an unbiased manner.

171

172

#### 173 Methods

174

- 175 Study design and population
- 176

177 For this cross-sectional, case-control study, we prospectively recruited subjects via 178 targeted invitation among the participants of a large-scale prospective cohort study of the 179 northern Netherlands (Lifelines Biobank; n=167,000).<sup>35</sup> Subjects were invited based solely on 180 their BP status and age. Following a strict selection procedure, 105 participants between 50 and 181 65 years of age satisfied both the BP criteria (see next paragraph) and the ophthalmic and 182 medical history inclusion criteria: unoperated eyes; best-corrected visual acuity  $\geq 0.8$ ; spherical 183 refractive error between -3 and +3 D; cylinder not exceeding 2 D; IOP  $\leq$  21 mmHg (non-contact 184 tonometer Tonoref II, Nidek, Aichi, Japan); no reproducibly abnormal VF test locations 185 (Frequency Doubling Technology [C20-1 screening mode], Carl Zeiss, Jena, Germany); no 186 family history of glaucoma; no ophthalmic, hematologic, or cardiovascular disease (except for 187 AHT), and no diabetes. We performed additional documentation of ophthalmic health with the 188 subsequent imaging sessions (see Data collection). We allocated participants to four non-189 overlapping groups: 1) low BP, 2) normal BP (controls), 3) treated AHT, and 4) untreated AHT. 190 Group definitions (see next paragraph) were based on previous epidemiological evidence on the association between BP status and glaucoma.<sup>15,16</sup> All participants provided written informed 191 192 consent. The ethics board of the University Medical Center Groningen approved the study 193 protocol (#NL61508.042.17). The study followed the tenets of the Declaration of Helsinki. 194 195 Blood pressure group definitions

196

We defined low BP (group 1) as both systolic and diastolic BP (SBP, DBP) lower than
the 10th percentiles of the age-matched population (110 mmHg and 65 mmHg, respectively),

199 without any AHT record. This criterion had to be confirmed on at least two previous, separate 200 occasions (ascertaining that subjects truly belonged to the tail of the distribution and did not 201 regress towards the mean). We defined untreated AHT (group 4) similarly, the criteria being 202 both SBP and DBP higher than the 90th percentiles of the age-matched population (149 mmHg 203 and 88 mmHg, respectively), verified at least twice previously. Subjects of this group were 204 aware of their BP status, but never made use of antihypertensive medication, by choice. For 205 treated AHT (group 3), we randomly invited participants documented as receiving (and still 206 making uninterrupted use of) antihypertensive medication for at least one year. Lastly, we 207 defined normal BP (group 2) as both SBP and DBP within 1 standard deviation (SD) from the mean of the age-matched population (SBP: 113 mmHg to 143 mmHg and DBP: 67 mmHg to 85 208 209 mmHg, measured on site) and no previous record of AHT.

210

211 Data collection

212

213 All participants were examined at the same time of the day (5:00 PM-6:30 PM) and were 214 not given any instructions regarding their routine prior to their visit. Following screening (see 215 previous section), we applied mydriatic drops that have been shown to not affect RBF 216 (tropicamide 0.5%).<sup>36</sup> After the participants had rested in a guiet room for 20 minutes, we 217 recorded BP from the brachial artery, in sitting position, with an automatic monitor (Omron M6 218 Comfort, Omron Healthcare, Kyoto, Japan). We averaged two readings, unless there was a 219 discrepancy of at least 10 mmHg in SBP or 5 mmHg in DBP, in which case we averaged three 220 readings. We also measured the weight and height of each participant.

For the imaging session, we selected, randomly if both eyes fulfilled the inclusion
 criteria, one eye per participant. We performed macular and optic nerve head (ONH) structural
 OCT imaging, as well as parafoveal OCT-A (Canon HS100 SD-OCT, Tokyo, Japan). The device
 automatically segments and quantifies macular RNFL (mRNFL) thickness and ganglion cell-

225 inner plexiform laver (GCIPL) within a 10-mm diameter circular region of interest (ROI) centered at the fovea (Figure 1A), a region which has been shown to be advantageous over the 226 commonly used 5-mm diameter ROI for mRNFL measurements.<sup>37</sup> It also reports peripapillary 227 228 RNFL (pRNFL) thickness at a 3.45-mm diameter circle centered at the ONH (Figure 1B). We 229 further subdivided pRNFL into temporal, superior, nasal, and inferior. We additionally acquired 230 two 6x6 mm OCT-A scans centered at the fovea (Figure 1C). We required an image guality of 231 7/10 or better, as well as the absence of any artifacts or segmentation errors for all OCT and 232 OCT-A scans, resulting in the exclusion of 9 out of the 105 subjects. 233 After registering and binarizing the signal of the en face OCT-A images, we calculated

the fractal dimension (FD) of the superficial vascular plexus, inside a 3-mm diameter circle
centered at the fovea (Figure 1C). We have previously provided details on FD and its
calculation, as well as on the specifications and repeatability of the Canon OCT-A.<sup>28,38</sup> In short,
FD represents the complexity of the branching pattern and is lower in conditions with sparser

238 vasculature, such as glaucoma.<sup>39</sup>

Lastly, we acquired two 45° high-quality and artifact-free fundus images (TRC-NW400, Topcon Corporation, Tokyo, Japan), centered at the ONH (Figure 1D). For each image, we derived the central retinal artery and vein equivalents (CRAE, CRVE; i.e., diameters) using the standardized Knudtson-Parr-Hubbard iteration, whose details and validation can be found elsewhere.<sup>28,40</sup> In short, we back-calculated vessel diameters using the 6 largest arteriolar and 6 largest venular branches, identified within a ring centered at the ONH (2 and 3 optic disc

diameters). We recorded the average CRAE and CRVE of two images.

246

247 Retinal blood flow and lower autoregulation limit

248

We calculated total retinal vascular resistance (RVR) using the measured FD, CRAE,
and CRVE of each participant, as well as population-based hematocrit values (Lifelines

medRxiv preprint doi: https://doi.org/10.1101/2021.01.14.21249808; this version posted January 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

251 Biobank), adjusted for age, sex, and blood pressure status. We have previously documented 252 the mathematics behind this Poiseuille-based model and its validation in vivo.<sup>28,41</sup> Subsequently, 253 we computed total RBF, using RVR and retinal perfusion pressure (RPP), a more precise 254 estimation of OPP for the retinal circulation<sup>28</sup>: 255  $RBF = \frac{RPP}{RVR}$ 256 (1) where RPP = (0.39·MAP + 10.1) - IOP mmHg and MAP =  $\frac{1}{3}$ SBP +  $\frac{2}{3}$ DBP is the mean arterial 257 258 pressure. 259 260 We defined LARL as the lowest RPP value for which RBF can be maintained constant 261 (Figure 2). At this critical point, the vasculature has reached its maximal autoregulatory capacity 262 and any further pressure drop will not trigger compensatory vasodilation, resulting in flow 263 reduction. We have previously shown that LARL can be approximated as: 264 265 LARL = RBF·RVR<sub>max</sub> (2) 266 where RVR<sub>max</sub> is an upper bound observed in a population.<sup>28</sup> 267 268 In this study, we defined RVR<sub>max</sub> as the 95th percentile of the RVR distribution. Due to the 269 possible occurrence of structural remodeling in retinal vessels belonging to subjects with AHT, 270 we separated the RVR distributions of the non-hypertensives (groups 1 and 2) and hypertensives (groups 3 and 4).<sup>12</sup> 271 272 Lastly, for each participant, we defined the autoregulatory reserve (AR) as the difference 273 between measured RPP and predicted LARL (Figure 2). 274 275

276 Statistical analysis

277

278 For the first part of the analysis, to establish the existence of a U-shaped association (if 279 any), we univariably compared structural OCT metrics (mRNFL, GCIPL, and pRNFL) between 280 the four BP groups. For the second part of the analysis, to investigate whether any vascular 281 factors could possibly explain this association, we univariably compared RVR, RBF, and AR 282 between the groups. For the last part of the analysis, we performed mediation analysis to 283 examine whether the vascular metrics lie in the explanatory pathway of the relationship between 284 MAP and the structural OCT metrics that were significant in the first part of the analysis. 285 We described normally distributed variables with the mean and standard deviation (SD) 286 and variables with a skewed distribution with the median and interguartile range (IQR). We used 287 one-way ANOVA with post hoc tests for group mean comparisons, adjusting for potential 288 confounders. To account for multiple testing, we implemented the Tukey HSD correction. We 289 applied Levene's test to check for equality of variances. Whenever ANOVA assumptions were 290 not met, we used non-parametric tests, Welch's one-way ANOVA with the Games-Howell 291 correction, or quantile regression. To determine a mediation effect, we used Baron and Kenny's mediation steps.<sup>42</sup> In short, 292 293 a vascular factor M was considered a mediator of the effect of MAP (X) on structural OCT (Y), if 294 the following were true in linear regression analysis: 295 a) X was a significant predictor of Y (Y~X). 296 b) X was a significant predictor of M (M~X). 297 c) When M was added to the model  $(Y \sim X + M)$ , M was a significant predictor of Y and the 298 significance of X as a predictor of Y was reduced. 299 We verified these findings by using the Sobel test for indirect effects. Mediation analysis was 300 performed separately for the low BP group together with the controls, the treated AHT group

301 together with the controls, and the untreated AHT group together with the controls. RBF, RVR,

- 302 and AR were examined as potential mediators.
- All analyses were performed using R (version 3.3.3; R Foundation for Statistical
- 304 Computing, Vienna, Austria) and SPSS (version 26; IBM Corp., Armonk, NY). A *P* value of 0.05
- 305 or less was considered statistically significant.
- 306
- 307 Results
- 308
- 309 In total, 96 eyes of 96 subjects fulfilled all the criteria and were included in the analysis.

310 Table 1 displays the characteristics of the population, stratified by BP status. Sex and BMI were

311 significantly different between groups, aside from BP. As expected, the low BP group comprised

312 almost exclusively females, while higher BMI was present in the hypertensive groups.<sup>43,44</sup> Other

313 factors that could affect the comparisons, such as age, IOP, spherical equivalent (SEQ), and

- 314 ONH area, were similar between groups.
- 315
- 316 **Table 1.** Characteristics of the study population.

	Group 1 (Low BP)	Group 2 (Normal BP)	Group 3 (Treated AHT)	Group 4 (Untreated AHT)	<i>P</i> value
Group size <i>(N)</i>	31	21	26	18	
Age; years [mean (SD)]	56.1 (4.4)	55.9 (4.7)	56.4 (4.8)	57.2 (4.6)	0.81
Sex; % female	93.5	47.6	42.3	44.4	<0.001
SBP; mmHg [mean (SD)]	106 (9)	126 (6)	142 (18)	159 (22)	<0.001
DBP; mmHg [mean (SD)]	66 (6)	79 (6)	86 (11)	99 (8)	<0.001

BMI; kg⋅m <sup>-2</sup> [median (IOB)]	22.1 (21.2 to 24.3)	23.3 (22.1 to 26.5)	26.9 (24 7 to 29 8)	27.3	<0.001
	(21.2 to 24.3)	(22.1 to 20.3)	(24.7 to 25.0)	(24.0 10 20.4)	
Smoking; % ever	22.6	38.1	30.8	38.9	0.57
IOP; mmHg [mean (SD)]	13.9 (3.0)	13.2 (3.1)	14.3 (3.0)	14.6 (3.7)	0.56
SEQ; D [mean (SD)]	-0.10 (1.41)	+0.27 (1.67)	-0.23 (1.55)	-0.68 (1.69)	0.31
ONH area; mm <sup>2</sup> [median (IQR)]	1.89 (1.69 to 2.24)	1.96 (1.71 to 2.20)	1.94 (1.72 to 2.31)	2.00 (1.78 to 2.29)	0.75

BP, blood pressure; AHT, arterial hypertension; SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; IOP, intraocular pressure; SEQ, spherical equivalent; ONH, optic nerve head.

317

### 318 Structural metrics

319

320 Table 2 and Figure 3 present the comparison of structural OCT metrics across the four 321 BP groups. Adjusted post hoc comparisons revealed that, compared to the controls, GCIPL was significantly thinner in the low BP group ( $P_{adj} = 0.013$ ), the treated AHT group ( $P_{adj} = 0.007$ ), and 322 323 the untreated AHT group ( $P_{adj}$  = 0.007). The mRNFL was also thinner, but this was only 324 significant for the treated AHT group ( $P_{adi} = 0.001$ ). Interestingly, mRNFL in treated 325 hypertensives was even significantly thinner than in untreated hypertensives ( $P_{adj} = 0.033$ ). 326 Figure 3 shows the characteristic (inverse) U shape for the macular OCT metrics. There was no 327 clear effect of BP group on the mean pRNFL. However, treated hypertensives had a thinner 328 temporal pRNFL (*P<sub>adj</sub>* = 0.045) than normotensives. Also, inferior pRNFL was borderline thinner 329 in subjects with low BP ( $P_{adj} = 0.083$ ) and clearly thinner in both treated and untreated 330 hypertensives ( $P_{adj}$  = 0.034 and 0.033, respectively). Sex and BMI did not confound any of the

associations (all *P* values >> 0.05) and this was still true after the omission of any group from

the analysis.

333

334 **Table 2.** Structural OCT metrics as a function of BP status.

	Group 1 (Low BP)	Group 2 (Normal BP)	Group 3 (Treated AHT)	Group 4 (Untreated AHT)	<i>P</i> value
GCIPL; μm [mean (SD)]	53.6 (2.7)	56.2 (3.0)	53.4 (3.3)	53.1 (2.5)	0.002
mRNFL; μm [mean (SD)]	37.7 (3.3)	39.8 (3.4)	36.0 (2.8)	38.7 (3.4)	0.001
Total pRNFL; μm [mean (SD)]	99.4 (8.2)	103.1 (10.1)	96.9 (9.2)	100.3 (8.8)	0.14
Temporal pRNFL; μm [mean (SD)]	71.8 (10.5)	74.0 (8.1)	65.5 (9.5)	72.6 (15.3)	0.038
Superior pRNFL; μm [mean (SD)]	119.6 (14.7)	124.1 (16.7)	119.5 (13.5)	126.1 (16.6)	0.36
Nasal pRNFL; μm [mean (SD)]	82.2 (11.2)	80.6 (14.1)	81.4 (11.4)	80.6 (14.0)	0.96
Inferior pRNFL; μm [mean (SD)]	124.5 (12.9)	134.0 (13.3)	122.7 (14.3)	121.5 (15.7)	0.019

OCT, optical coherence tomography; BP, blood pressure; AHT, arterial hypertension; GCIPL, ganglion cell-inner plexiform layer; SD, standard deviation; mRNFL, macular retinal nerve fiber layer; pRNFL, peripapillary retinal nerve fiber layer.

335

336 Vascular metrics

337

338 Figure 4 displays RBF, RVR, and AR as a function of BP status. There were differences

in RBF between groups (P = 0.034), but after adjusting for multiple comparisons RBF was only

340 significantly lower in the low BP group when compared to the untreated AHT group ( $P_{adi}$  = 0.043). RVR was also different between groups ( $P = 9.0 \cdot 10^{-9}$ ), with the additional presence of a 341 larger variance in the treated AHT group (Levene's test: P = 0.002). With regards to AR, the 342 343 unequal variances were also statistically significant (Levene's test: P = 0.0002), showing that, 344 unlike any other group, treated hypertensives could have either a large or a small AR. As can be 345 better seen in Figure 5 and Supplementary Table S1, the low BP group had a significantly 346 smaller AR than the control group, regardless of AR quantile compared. Conversely, the 347 untreated hypertensives had a significantly larger AR than the control group, regardless of 348 guantile compared. However, there was a mixed response in the treated AHT group: the AR 349 was significantly smaller than that of the controls for small quantiles, while it was similar or 350 larger for larger quantiles. In addition, correlation analysis within the treated AHT group revealed 351 that the smaller AR quantiles corresponded to the lowest MAP values (Pearson's r = 0.45, P =352 0.020), i.e., to the most intensively controlled hypertensives. Again, sex and BMI did not 353 confound these associations.

354

355 Mediation analysis

356

357 Results from mediation analysis regarding the effect of BP status on GCIPL are 358 presented in Table 3. RBF was mediating the association of GCIPL with BP within the combined 359 low BP group and controls, while RVR was mediating the same association within the combined 360 untreated AHT group and controls. RVR and AR were both independently mediating the 361 association of GCIPL with BP within the combined treated AHT group and controls. In the 362 complete model (GCIPL~MAP+RVR+AR), which accounts for the covariance between RVR and 363 AR, the opposite, real effect of AR became visible, that is, small AR was associated with thinner 364 GCIPL (see Discussion section). We did not observe any vascular mediation for the effect of BP 365 status on RNFL metrics.

# 366

### 367 **Table 3.** Effect of BP status on GCIPL: mediation analysis.

	Low BP + controls (Group 1 + Group 2)		Controls + treated AHT (Group 2 + Group 3)		Controls + untreated AHT (Group 2 + Group 4)	
	Effect	<i>P</i> value	Effect	<i>P</i> value	Effect	<i>P</i> value
Mediation step 1:						
GCIPL ~ MAP	bмар = 0.09	0.052	b <sub>мар</sub> = -0.10	0.043	b <sub>мар</sub> = -0.07	0.032
Mediation step 2:					•	
RBF ~ MAP	b <sub>MAP</sub> = 0.27	0.020	N/A	N/A	N/A	N/A
RVR ~ MAP	N/A	N/A	b <sub>MAP</sub> = 0.005	0.008	b <sub>мар</sub> = 0.005	0.0003
AR ~ MAP	N/A	N/A	b <sub>MAP</sub> = 0.17	0.015	N/A	N/A
Mediation step 3:						
GCIPL ~ MAP + RBF	b <sub>MAP</sub> = 0.05	0.30	N/A	N/A	N/A	N/A
	b <sub>RBF</sub> = 0.16	0.003	N/A	N/A	N/A	N/A
GCIPI ~ MAP + RVR	N/A	N/A	b <sub>MAP</sub> = -0.04	0.42	b <sub>MAP</sub> = -0.03	0.51
	N/A	N/A	b <sub>RVR</sub> = -11.87	0.001	b <sub>RVR</sub> = -10.23	0.022
GCIPL ~ MAP + AR	N/A	N/A	b <sub>мар</sub> = -0.06	0.21	N/A	N/A
	N/A	N/A	b <sub>AR</sub> = -0.21	0.042	N/A	N/A
	N/A	N/A	b <sub>MAP</sub> = -0.04	0.40	N/A	N/A
GCIPL ~ MAP + RVR + AR	N/A	N/A	b <sub>RVR</sub> = -27.37	0.001	N/A	N/A
	N/A	N/A	b <sub>AR</sub> = 0.47	0.032	N/A	N/A
Sobel test	0.059		RVR: <b>0.041</b> ; AR: 0.095		0.031	

BP, blood pressure; GCIPL, ganglion cell-inner plexiform layer; AHT, arterial hypertension; MAP, mean arterial pressure; RBF, retinal blood flow; RVR, retinal vascular resistance; AR, autoregulatory reserve; *N/A*, not applicable.

368

### 369 Discussion

370

In this study, we reported three main findings. Firstly, there exists an inverse U-shaped effect between blood pressure status and structural OCT metrics (GCIPL and RNFL), with both low and high blood pressure being associated with thinning of the inner retinal layers. Secondly, despite the existence of retinal blood flow autoregulation, only a small autoregulatory reserve is present in individuals with low blood pressure, as well as in individuals with intensively treated arterial hypertension. Lastly, this compromised capacity for retinal blood flow regulation explains (mediates) the effect of blood pressure status on the GCIPL.

378

#### 379 Low blood pressure

380

This is, to our knowledge, the first study to uncover an association between low BP and thinning of the inner retina in ophthalmologically healthy subjects. This relationship and its vascular mediation were more pronounced for the GCIPL, which has been shown to be the main layer of early NTG manifestation.<sup>45</sup> In addition, the association was entirely mediated by RBF (no effect of sex, BMI, or other confounders in our population).

Indeed, we have previously shown that LARL for subjects without AHT corresponds to a realistic SBP/DBP of ~105/65 mmHg (or even higher if IOP is above average).<sup>28</sup> Since, in the present study, the average BP reading for the low BP group was at 106/66 mmHg, our finding that this group had a borderline lower RBF (Figure 4, Table 3) and a considerably smaller AR

(Figure 5, Table S1) than controls is in line with our estimations and the general concept ofautoregulation.

Population studies have failed to report this association between low BP and GCIPL
 thickness, possibly due to the implementation of linear models, but an explanation due to
 differences in genetic background cannot be excluded.<sup>33,34</sup> However, nonlinear models were
 used is studies with glaucoma as the outcome measure and, in line with our findings, there is
 evidence for the existence of increased glaucoma risk with low, usually diastolic or nocturnal,
 BP.<sup>13–16,18,46</sup>

398

399 Hypertension

400

401 Despite a slightly higher RBF and a considerably higher AR (Figures 4 and 5), untreated 402 hypertensives had thinner GCIPL, which has also been shown to be the location of first 403 progression in glaucoma patients with AHT.<sup>45</sup> This was mediated by RVR (Table 3), i.e., the 404 negative effect of increased BP to the GCIPL is explained by increased vascular resistance (but 405 not by reduced blood flow - see below). Nevertheless, it was the treated AHT group that 406 exhibited the most pronounced thinning and this was present in the majority of structural OCT 407 metrics (GCIPL, mRNFL, temporal pRNFL, inferior pRNFL). For this group, GCIPL thinning was 408 independently mediated by RVR and AR (Figure 5, Table 3). In the univariable models, large 409 RVR and large AR were both associated with thinner GCIPL, due to substantial covariance. 410 After controlling for the confounding effect of RVR, small AR was associated with thinner 411 GCIPL. This suggests that, in treated AHT, a combination of increased resistance and being 412 close to the autoregulatory tipping point explain the negative effect to the GCIPL. 413 GCIPL thinning without a decrease in RBF seems counterintuitive. However, even when

414 total RBF is largely unaffected, increased RVR results in increased blood velocity (i.e., reduced
415 transit time), shunting of flow, and reduced capillary density.<sup>47,48</sup> This could affect red blood cell

distribution and retinal oxygen extraction. Smaller AR was additionally present in intensively
treated subjects (Figure 4C, Figure 5, Table S1), which could mimic low BP and lead to
hypoperfusion of the RGCs. In this regard, our results reflect a possible effect of the combined
rightward shift of the autoregulation curve (due to atherosclerosis and arteriosclerosis) and the
variations of the measured RPP (Figure 2), due to BP fluctuations throughout the day. Lastly,
chronic AHT also results in endothelial dysfunction and, therefore, impaired autoregulation.<sup>49</sup>

422 A number of previous studies have also shown an effect of AHT on GCIPL and RNFL 423 thickness.<sup>21,29–32</sup> However, some population-based studies did not detect this relationship.<sup>33,34</sup> 424 Again, study design and analysis methods seem to be the most likely explanations for this 425 discrepancy. In all, the existence of thinner GCIPL in both low BP and AHT creates the 426 characteristic inverse U-shaped association. Regarding glaucoma risk, the role of AHT is 427 controversial. Most evidence points towards at least some benefit of timely AHT treatment, 428 possibly due to the prevention of microvascular damage, in combination with a slight IOP 429 lowering.<sup>24,50</sup> However, it has been suggested that aggressive treatment of AHT could 430 negatively affect glaucoma and our results also point towards this direction.<sup>20</sup> The confounding 431 contribution of individual antihypertensive medications, whether neuroprotective or detrimental, remains inconclusive.<sup>21–25</sup> 432

We would like to stress here that, since there are benefits to intensive BP control with regards to cardiovascular disease, our results should not be considered as a case for milder treatment of AHT in general.<sup>51,52</sup> However, since a J or U-shaped effect is reported in both fields when intensive treatment becomes too intensive, our results could be a starting point for discussion with cardiologists in individual cases where, for example, glaucoma continues to deteriorate despite adequate IOP control.<sup>53</sup>

439

440 'Chicken-egg' dilemma

441

From a theoretical standpoint, there exists a point in the pre-disease time course when the very first vascular deficits or the very first structural deficits manifest. A subsequent causal cascade of events would then result in further mutually mediated vascular and structural deterioration, sometimes leading to a glaucoma diagnosis. By definition, cross-sectional studies regarding perfusion in glaucoma cases are well past this critical point and cannot enhance our understanding of the process.

448 In this regard, our study's novelty lies in demonstrating that interdependent structural 449 and vascular deficits related to a long-debated cardiovascular risk factor (especially low BP) can 450 even be traced back to whom we perceive as ophthalmologically healthy subjects. These results 451 suggest that a subtle GON precursor remains rather elusive, albeit present early on. While this 452 observation adequately explains the claim that perfusion deficits are already present prior to 453 glaucoma, it does not fully resolve the 'chicken-egg' dilemma (we showed that vascular deficits 454 are present without glaucoma, but not necessarily without smaller structural deficits). However, 455 the existence of different mediators between MAP and GCIPL thickness with different BP status, 456 hints towards a preceding vascular component. For example, there is no parsimonious 457 explanation for an intensive antihypertensive treatment strategy following GCIPL thinning.

458

459 Study strengths and limitations

460

The main strength of this study was the strict selection process which allowed us to look at the true extremes of BP. This reduces the noise that usually characterizes larger population studies and results in indirect loss of power. In addition, our linearity-free assumptions and the categorizing of BP (rather than considering it as a continuous variable) allowed us to differentiate between BP status and uncover a U-shaped association that was previously elusive. Lastly, to our knowledge, this study is the first to provide a rigorous explanation of the

differential effect of BP status on retinal structure, by directly linking it to total RBF and itsautoregulation.

469 Due to the cross-sectional nature of our study, absence of data on the first occurrence of 470 AHT is a limitation. However, our threshold of an at least 1-year old diagnosis, together with the 471 selection procedure using multiple previous visits from another database, ensured no newly-472 diagnosed cases (almost all cases had been diagnosed before at least 3 years). Secondly, 473 RBF, RVR, and AR were not directly measured, but indirectly calculated by means of their 474 measured components and a previously validated model. Indeed, we have previously shown in 475 an independent validation dataset that these outcomes strongly correlate with in vivo blood flow metrics, as well as with structural metrics.<sup>28</sup> Unfortunately, there is currently no gold standard 476 477 way to quantify these parameters, but Doppler OCT is a frequently-used, promising tool. Our 478 predictive approach has the advantage of using more reproducible imaging techniques and, 479 most importantly, taking into account autoregulation limits. Combining these two methods could, 480 therefore, further finetune estimations. It should be also noted that our approach provides 481 information on the effect of static RBF autoregulation, but it is possible that BP status also 482 results in impairment of the autoregulatory latency, i.e., dynamic autoregulation. As such, our 483 results might only be part of a bigger underlying effect. Lastly, our population was predominantly 484 Caucasian; it is to be determined if the results can be generalized to other ethnicities.

485

In conclusion, we uncovered thinning of the GCIPL and RNFL related to both tails of the blood pressure distribution (inverse U-shaped effect) and to intensive treatment of AHT, in ophthalmically healthy individuals. We found that GCIPL thinning was associated with reduced autoregulatory capacity of retinal blood flow. This predisposition to glaucomatous damage could explain the frequent epidemiological finding of increased glaucoma risk in certain population subgroups, such as subjects with nocturnal blood pressure dipping or aggressively treated hypertension. Longitudinal studies are needed to confirm this postulation.

#### 493 References

- 495 1. Schuman JS, Hee MR, Puliafito CA, et al. Quantification of nerve fiber layer thickness in normal
  496 and glaucomatous eyes using optical coherence tomography. *Arch Ophthalmol.* 1995;113(5):586497 596.
- 498 2. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a
  499 randomised, multicentre, placebo-controlled trial. *Lancet.* 2015;385(9975):1295-1304.
- 3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma
  progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol.* 2002;120(10):12681279.
- 503 4. Drance SM. Some factors in the production of low tension glaucoma. *Br J Ophthalmol.*504 1972;56(3):229-242.
- 505 5. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. *Prog Retin Eye*506 *Res.* 2002;21(4):359-393.
- 507 6. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. *Science*.
  508 1991;254(5035):1178-1181.
- 509 7. Jia Y, Tan O, Tokayer J, et al. Split-spectrum amplitude-decorrelation angiography with optical
  510 coherence tomography. *Opt Express*. 2012;20(4):4710.
- 8. Wojtkowski M, Leitgeb R, Kowalczyk A, Bajraszewski T, Fercher AF. In vivo human retinal
  imaging by Fourier domain optical coherence tomography. *J Biomed Opt.* 2002;7(3):457.
- 9. Yarmohammadi A, Zangwill LM, Diniz-Filho A, et al. Relationship between Optical Coherence
  Tomography Angiography Vessel Density and Severity of Visual Field Loss in Glaucoma.
  Ophthalmology. 2016;123(12):2498-2508.
- 516 10. Yoshioka T, Song Y, Kawai M, et al. Retinal blood flow reduction in normal-tension glaucoma
  517 with single-hemifield damage by Doppler optical coherence tomography. *Br J Ophthalmol.*518 2021;105(1):124-130.
- 519 11. Hwang JC, Konduru R, Zhang X, et al. Relationship among visual field, blood flow, and neural
  520 structure measurements in glaucoma. *Invest Ophthalmol Vis Sci.* 2012;53(6):3020-3026.
- 521 12. Hayreh SS. Blood flow in the optic nerve head and factors that may influence it. *Prog Retin Eye*

522 Res. 2001;20(5):595-624.

- 523 13. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest
  524 glaucoma trial. *Ophthalmology*. 2007;114(11):1965-1972.
- 525 14. Leske MC, Wu S-Y, Hennis A, Honkanen R, Nemesure B, BESs Study Group. Risk factors for
  526 incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology*. 2008;115(1):85-93.

527 15. Zheng Y, Wong TY, Mitchell P, Friedman DS, He M, Aung T. Distribution of Ocular Perfusion
528 Pressure and Its Relationship with Open-Angle Glaucoma: The Singapore Malay Eye Study. *Invest*529 *Ophthalmol Vis Sci.* 2010;51(7):3399.

- 530 16. Memarzadeh F, Ying-Lai M, Chung J, Azen SP, Varma R, Los Angeles Latino Eye Study Group.
  531 Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study.
  532 *Invest Ophthalmol Vis Sci.* 2010;51(6):2872-2877.
- 533 17. Ramdas WD, Wolfs RCW, Hofman A, de Jong PTVM, Vingerling JR, Jansonius NM. Ocular
  534 perfusion pressure and the incidence of glaucoma: real effect or artifact? The Rotterdam Study.
  535 *Invest Ophthalmol Vis Sci.* 2011;52(9):6875-6881.
- 536 18. Bowe A, Grünig M, Schubert J, et al. Circadian Variation in Arterial Blood Pressure and
  537 Glaucomatous Optic Neuropathy—A Systematic Review and Meta-Analysis. *American Journal of*538 *Hypertension*. 2015;28(9):1077-1082.
- 539 19. Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and primary open-angle
  540 glaucoma: a meta-analysis. *Am J Ophthalmol.* 2014;158(3):615-627.e9.
- 541 20. Topouzis F, Wilson MR, Harris A, et al. Association of open-angle glaucoma with perfusion
  542 pressure status in the Thessaloniki Eye Study. *Am J Ophthalmol.* 2013;155(5):843-851.
- 543 21. Chong RS, Chee M-L, Tham Y-C, et al. Association of Antihypertensive Medication with Retinal
  544 Nerve Fiber Layer and Ganglion Cell-Inner Plexiform Layer Thickness. *Ophthalmology*.
  545 2020;31:S0161-6420(20)30739-9. doi:10.1016/j.ophtha.2020.07.051
- 546 22. Müskens RPHM, de Voogd S, Wolfs RCW, et al. Systemic antihypertensive medication and
  547 incident open-angle glaucoma. *Ophthalmology*. 2007;114(12):2221-2226.
- 548 23. Zheng W, Dryja TP, Wei Z, et al. Systemic Medication Associations with Presumed Advanced or
  549 Uncontrolled Primary Open-Angle Glaucoma. *Ophthalmology*. 2018;125(7):984-993.
- 550 24. Horwitz A, Klemp M, Jeppesen J, Tsai JC, Torp-Pedersen C, Kolko M. Antihypertensive

551 Medication Postpones the Onset of Glaucoma: Evidence from a Nationwide Study. *Hypertension*.
552 2017;69(2):202-210.

- 25. Pappelis K, Loiselle AR, Visser S, Jansonius NM. Association of Systemic Medication Exposure
  with Glaucoma Progression and Glaucoma Suspect Conversion in the Groningen Longitudinal
  Glaucoma Study. *Invest Ophthalmol Vis Sci.* 2019;60(14):4548-4555.
- 556 26. Asefa NG, Neustaeter A, Jansonius NM, Snieder H. Autonomic Dysfunction and Blood Pressure
  557 in Glaucoma Patients: The Lifelines Cohort Study. *Invest Ophthalmol Vis Sci.* 2020;61(11):25.
- 558 27. Riva CE, Grunwald JE, Petrig BL. Autoregulation of human retinal blood flow. An investigation
  559 with laser Doppler velocimetry. *Invest Ophthalmol Vis Sci*. 1986;27(12):1706-1712.
- 28. Pappelis K, Choritz L, Jansonius N. Microcirculatory model predicts blood flow and
  autoregulation range in the human retina: in vivo investigation with Laser Speckle Flowgraphy. *Am J Physiol Heart Circ Physiol.* 2020;319(6):H1253-H1273. doi:10.1152/ajpheart.00404.2020
- 29. Lee SH, Lee WH, Lim HB, Jo YJ, Kim JY. THICKNESSES OF CENTRAL MACULAR, RETINAL
  NERVE FIBER, AND GANGLION CELL INNER PLEXIFORM LAYERS IN PATIENTS WITH
  HYPERTENSION. *Retina*. 2019;39(9):1810-1818.
- 30. Lim HB, Lee MW, Park JH, Kim K, Jo YJ, Kim JY. Changes in Ganglion Cell–Inner Plexiform
  Layer Thickness and Retinal Microvasculature in Hypertension: An Optical Coherence Tomography
  Angiography Study. *Am J Ophthalmol.* 2019;199:167-176.
- 31. Akay F, Gündoğan FC, Yolcu U, Toyran S, Tunç E, Uzun S. Retinal structural changes in
  systemic arterial hypertension: an OCT study. *Eur J Ophthalmol.* 2016;26(5):436-441.
- 571 32. Sahin OZ, Sahin SB, Ayaz T, et al. The impact of hypertension on retinal nerve fiber layer
  572 thickness and its association with carotid intima media thickness. *Blood Press*. 2015;24(3):178-184.
- 573 33. Tham Y-C, Chee ML, Dai W, et al. Profiles of Ganglion Cell-Inner Plexiform Layer Thickness in a
  574 Multi-Ethnic Asian Population. *Ophthalmology*. 2020;127(8):1064-1076.
- 575 34. Koh VT, Tham Y-C, Cheung CY, et al. Determinants of Ganglion Cell–Inner Plexiform Layer
  576 Thickness Measured by High-Definition Optical Coherence Tomography. *Invest Ophthalmol Vis Sci.*577 2012;53(9):5853.
- 578 35. Ende MY van der, van der Ende MY, Hartman MHT, et al. The LifeLines Cohort Study:
  579 Prevalence and treatment of cardiovascular disease and risk factors. *Int J Cardiol.* 2017;228:495580 500.

581 36. Luft N, Wozniak PA, Aschinger GC, et al. Measurements of Retinal Perfusion Using Laser
582 Speckle Flowgraphy and Doppler Optical Coherence Tomography. *Invest Ophthalmol Vis Sci.*583 2016;57(13):5417-5425.

- 584 37. Heikka T, Cense B, Jansonius NM. Retinal layer thicknesses retrieved with different
- segmentation algorithms from optical coherence tomography scans acquired under different signalto-noise ratio conditions. *Biomed Opt Express*. 2020;11(12):7079.
- 587 38. Pappelis K, Jansonius NM. Quantification and Repeatability of Vessel Density and Flux as
  588 Assessed by Optical Coherence Tomography Angiography. *Transl Vis Sci Technol.* 2019;8(3):3.
- 39. Al-Nosairy KO, Prabhakaran GT, Pappelis K, Thieme H, Hoffmann MB. Combined Multi-Modal
  Assessment of Glaucomatous Damage with Electroretinography and Optical Coherence
  Tomography/Angiography. *Transl Vis Sci Technol.* 2020;9(12):7.
- 40. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BEK. Revised formulas for
  summarizing retinal vessel diameters. *Curr Eye Res.* 2003;27(3):143-149.
- 41. Takahashi T, Nagaoka T, Yanagida H, et al. A mathematical model for the distribution of
  hemodynamic parameters in the human retinal microvascular network. *J Biorheol*. 2009;23(2):77-86.

42. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological
research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol*. 1986;51(6):11731182.

599 43. Tigchelaar EF, Zhernakova A, Dekens JAM, et al. Cohort profile: LifeLines DEEP, a prospective,
600 general population cohort study in the northern Netherlands: study design and baseline
601 characteristics. *BMJ Open.* 2015;5(8):e006772.

- 44. Slagter SN, van Waateringe RP, van Beek AP, van der Klauw MM, Wolffenbuttel BHR, van
  Vliet-Ostaptchouk JV. Sex, BMI and age differences in metabolic syndrome: the Dutch Lifelines
  Cohort Study. *Endocr Connect.* 2017;6(4):278.
- 45. Marshall HN, Andrew NH, Hassall M, et al. Macular Ganglion Cell–Inner Plexiform Layer Loss
  Precedes Peripapillary Retinal Nerve Fiber Layer Loss in Glaucoma with Lower Intraocular
  Pressure. *Ophthalmology*. 2019;126(8):1119-1130.

46. Melgarejo JD, Lee JH, Petitto M, et al. Glaucomatous Optic Neuropathy Associated with
Nocturnal Dip in Blood Pressure: Findings from the Maracaibo Aging Study. *Ophthalmology*.
2018;125(6):807-814.

611	47. Leskova W, Warar R, Harris NR. Altered Retinal Hemodynamics and Mean Circulation Time in
612	Spontaneously Hypertensive Rats. Invest Ophthalmol Vis Sci. 2020;61(10):12.

- 613 48. Chua J, Chin CWL, Hong J, et al. Impact of hypertension on retinal capillary microvasculature
  614 using optical coherence tomographic angiography. *J Hypertens*. 2019;37(3):572-580.
- 615 49. Delles C, Michelson G, Harazny J, Oehmer S, Hilgers KF, Schmieder RE. Impaired endothelial
  616 function of the retinal vasculature in hypertensive patients. *Stroke*. 2004;35(6):1289-1293.
- 617 50. Klein BEK, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure:
- 618 longitudinal perspective: the Beaver Dam Eye Study. *Br J Ophthalmol*. 2005;89(3):284-287.
- 51. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular
- 620 disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-967.
- 52. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *J Hypertens*.
  2019;37(1):226.
- 53. Böhm M, Schumacher H, Teo KK, et al. Achieved diastolic blood pressure and pulse pressure at
  target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients:
  results from ONTARGET and TRANSCEND trials. *Eur Heart J.* 2018;39(33):3105-3114.
- 626

# 628 Figure 1.

629

630	Structural (A-B) and vascular (C-D) regions of interest. A) Macular retinal nerve fiber layer
631	(mRNFL) and ganglion cell-inner plexiform layer (GCIPL) thicknesses measured within the
632	larger (10-mm diameter) circle centered at the fovea, excluding the innermost 1-mm diameter
633	circle and the nasal sector of the outer ring. B) Peripapillary RNFL (pRNFL) measured at a circle
634	of 3.45-mm diameter centered at the optic nerve head (ONH). C) Optical Coherence
635	Tomography-Angiography (OCT-A) scan of 6x6 mm centered at the fovea. Signal intensity
636	inside the innermost 3-mm diameter circle is binarized in flow (black) and non-flow (white). D)
637	45° fundus image centered at the ONH. The 6 largest arterioles and 6 largest venules between
638	rings of 2 and 3 optic disc diameters are marked in blue.
639	
640	Figure 2.
641	
642	Theoretical autoregulation curve (axes in arbitrary units). Retinal blood flow (RBF) is displayed
643	as a function of retinal perfusion pressure (RPP). Within the autoregulation range, blood flow is
644	maintained constant. The distance of the actual (measured) RPP from the lower autoregulation
645	limit (LARL) is the autoregulatory reserve (AR).
646	
647	Figure 3.
648	
649	Ganglion cell-inner plexiform layer (GCIPL), macular retinal nerve fiber layer (mRNFL), and
650	peripapillary retinal nerve fiber layer (pRNFL) as a function of blood pressure (BP) status.
651	Significant differences after post hoc comparisons (adjusted for multiple testing) are marked.
652	The thicker layers observed in the control group (normal BP) than in the low BP or arterial

653 hypertension (AHT) groups create a characteristic (inverse) U shape.

654	
655	Figure 4.
656	
657	Absolute total retinal blood flow (RBF), retinal vascular resistance (RVR), and autoregulatory
658	reserve (AR) as a function of blood pressure (BP) status. Significant differences after post hoc
659	comparisons (adjusted for multiple testing) are marked. With increasing BP, RBF increases less
660	than RVR, resulting in an autoregulation effect visible in the first panel. A statistically significant
661	larger variability is observed for the AR of treated hypertensives (third panel), suggesting that
662	subjects in this group can be very close or very far from the lower autoregulation limit.
663	
664	Figure 5.
665	
666	Quantile regression models for autoregulatory reserve (AR) at each blood pressure (BP) status.
667	Parameter estimates (y-axis) represent the relative AR (compared to controls) for every AR
668	decile (x-axis). Low BP individuals (left panel) have a smaller AR than controls (y<0), while
669	individuals with untreated arterial hypertension (AHT; right panel) have a larger AR than controls
670	(y>0). Individuals with treated AHT (middle panel) have a smaller AR only when intensively
671	treated (leftmost deciles).
672	
673	
674	
675	
676	
677	
678	
679	

# 680 **Figure 1**

# 681



682

683

684 Figure 2



RPP (a.u.)



687





